179 related articles for article (PubMed ID: 28651494)
21. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
22. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
23. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
24. miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.
Xu S; Yi XM; Zhang ZY; Ge JP; Zhou WQ
Mol Med Rep; 2016 Dec; 14(6):5025-5032. PubMed ID: 27779679
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
27. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
28. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
29. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
Benko G; Spajić B; Krušlin B; Tomas D
Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
[TBL] [Abstract][Full Text] [Related]
31. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
32. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K; Roettger L; Kluth M; Hube-Magg C; Simon R; Lebok P; Minner S; Tsourlakis MC; Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Wilczak W; Huland H; Schlomm T; Steurer S; Krech T
Oncol Rep; 2015 Sep; 34(3):1211-20. PubMed ID: 26134445
[TBL] [Abstract][Full Text] [Related]
33. Effect of age on biochemical recurrence after radical prostatectomy.
Ozden C; Aktas BK; Bulut S; Erbay G; Tagci S; Gokkaya CS; Baykam MM; Memis A
Kaohsiung J Med Sci; 2017 Feb; 33(2):91-95. PubMed ID: 28137417
[TBL] [Abstract][Full Text] [Related]
34. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
[TBL] [Abstract][Full Text] [Related]
35. The Thoc1 ribonucleoprotein and prostate cancer progression.
Chinnam M; Wang Y; Zhang X; Gold DL; Khoury T; Nikitin AY; Foster BA; Li Y; Bshara W; Morrison CD; Payne Ondracek RD; Mohler JL; Goodrich DW
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25296641
[TBL] [Abstract][Full Text] [Related]
36. DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
Bouchaert P; Guerif S; Debiais C; Irani J; Fromont G
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1179-85. PubMed ID: 22494583
[TBL] [Abstract][Full Text] [Related]
37. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
Jones TD; Koch MO; Lin H; Cheng L
BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
Tassidis H; Brokken LJ; Jirström K; Ehrnström R; Pontén F; Ulmert D; Bjartell A; Härkönen P; Wingren AG
Int J Cancer; 2010 May; 126(10):2296-307. PubMed ID: 19795453
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1.
Chen JH; Liang YX; He HC; Chen JY; Lu JM; Chen G; Lin ZY; Fu X; Ling XH; Han ZD; Jiang FN; Zhong WD
Int J Biol Macromol; 2015 Nov; 81():615-23. PubMed ID: 26314905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
